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Correlation analysis identifies multiple measurements of 
material from the same sample. The analysis of 45 datasets 
(including 4913 patients) revealed that erroneous sample 
annotation, affecting 40 % of the analyzed datasets, may be 
a more widespread phenomenon than previously thought. 
Removal of erroneously labelled samples may influence 
the results of the statistical evaluation in some datasets. 
Our methods may help to identify individual datasets that 
contain numerous discrepancies and could be routinely 
included into the statistical analysis of clinical gene expres-
sion data.
Keywords Gene expression · Microarray · 
Misannotation · Quality control · Male–female classifier
Introduction
The generation of large gene expression datasets presents 
a logistic challenge that extends from the initial procure-
ment and storage of tissue samples, through laboratory 
procedures, to bioinformatic data processing and analysis. 
Although anticipated to be low, little is known about the 
actual frequency of sample mix-up during this multi-step 
process. The reasons for sample identity being swapped 
between individuals are diverse, and these events are dif-
ficult to pinpoint retrospectively with absolute certainty. 
In datasets with roughly balanced frequencies of male and 
female individuals, it can be assumed that approximately 
half of the mix-ups will result in sex mislabeling. These 
cases can be identified by assessment of genes with male- 
or female-specific expression. Other commonly annotated 
clinicopathological parameters, such as tumor stage, would 
also be affected by mislabeling, but the lack of genes that 
exhibit for instance a reliable stage-specific expression 
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pattern makes the standardized assessment of these param-
eters unsuitable.
Few attempts have been made to systematically iden-
tify sample mix-ups in public gene expression datasets. 
The MixupMapper software (Westra et al. 2011) requires 
DNA sequence data (SNP) in addition to gene expression 
data. However, the majority of previous studies are based 
exclusively on gene expression data. Recent approaches 
use the expression of the X-chromosomal gene XIST and 
genes located on the Y chromosome for the discrimina-
tion between male and female samples in the analysis of 
single datasets. However, these methods are not generaliz-
able because of the lack of normalization across datasets (‘t 
Hoen et al. 2013; Broman et al. 2015).
To gain insight into frequencies of sample annotation 
discrepancies in publicly available gene expression data-
sets, we established a male–female classifier based on gene 
expression array data. In addition, correlations between 
expression values for pairs of samples were assessed to 
identify multiple measurements of tissue from the same 
individual, as this represents an additional hypothetical 
source of inconsistencies with regard to sample annotation.
Methods
In this investigation, 45 publicly available MIAME-compli-
ant sample collections were included (see Tables 1, 2 for 
details), all with accessible gene expression array data and 
available information on male or female sex for each study 
subject. In total, the studies comprised 4913 patients (3034 
females, 1879 males). Gene expression array data and 
information on male or female sex for each study subject 
were accessed from the Gene Expression Omnibus (GEO) 
or directly from the authors’ Web site (Edgar et al. 2002; 
Shedden et al. 2008; Bild et al. 2006). Only datasets using 
the AffymetrixGeneChip© HG-U133A or HG-U133 Plus 
2.0 were included in this analysis.
To construct the classifier, we proceeded in three steps: 
1. selection of probe sets with male- or female-specific 
expression, 2. dataset normalization to enable analysis of 
unlabelled cohorts and cohorts comprising only female or 
only male patients, and 3. combination of evidence from 
male- and female-specific probe sets into a final classi-
fier that categorizes each sample as “correctly classified,” 
“misclassified,” or “unconfident.” In each step (1–3) a like-
lihood-based strategy was applied that ensures robustness 
against outliers (Algorithms 1–3 in Suppl. material).
The initial probe set selection was based on 10 pub-
licly available non-small cell lung cancer (NSCLC) gene 
expression datasets analyzed on the AffymetrixGeneChip© 
HG-U133A or HG-U133 Plus 2.0 array (Suppl. material: 
Algorithm 1). For each sample, sex information and gene 
expression measurements for 22,277 probe sets were avail-
able. Only seven probe sets achieved median male–female 
classification accuracy above 75 % and only five above 
90 %. The top four probe sets were included in the classifier 
(Table 3). Two of them map to the XIST gene (221728_x_at 
and 214218_s_at), located on the X chromosome, and the 
other two to RPS4Y1 (201909_at) and DDX3Y (205000_
at), respectively, both located on the Y chromosome. XIST 
is expressed from the inactive female X chromosome and 
silenced in men. This is illustrated in one NSCLC dataset 
(GSE31210), with high expression of XIST (221728_x_at) 
observed in all patients labelled as female (Fig. 1), but 
only in one sample labelled as male. Hence, this exception 
Table 1  Overview of analyzed datasets
Tissue collections and gene array datasets analyzed by the male–female classifier, if available identified by their Gene Expression Omnibus 
(GEO) Series (GSE) number
Type Cohorts Sample size (female/male)




Colon cancer GSE33113, GSE12945, GSE31595, GSE4271, GSE1433, GSE17536, GSE17537 769
(358/411)
Other cancer GSE5720, GSE4107, GSE42952, GSE34111, GSE31684 200
(64/136)
Non-cancer GSE19027, GSE17913, GSE23343, GSE25462, GSE7821, GSE20950, GSE24427 408
(219/189)




Ovarian cancer Bild, GSE14764, GSE19829, GSE26712 426
(426/0)
Prostate cancer GSE17951, GSE25136, GSE3325, GSE8218 399
(0/399)
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Table 2  Detailed description of analyzed datasets
Overview over the studied tissue collections and gene array data
Cohort # Female # Male # Total Type (disease or subject of study)
GSE37745 89 107 196 NSCLC
Shedden 220 223 443 NSCLC
GSE31547 36 14 50 NSCLC + controls
GSE29013 17 38 55 NSCLC
GSE14814 23 67 90 NSCLC
GSE4573 47 82 129 NSCLC
GSE31210 109 95 204 NSCLC
GSE19188 23 59 82 NSCLC
GSE31546 14 3 17 NSCLC
GSE10445 16 56 72 NSCLC
GSE4107 12 10 22 Colorectal cancer
GSE33113 48 42 90 Colorectal cancer
GSE31595 22 15 37 Colorectal cancer
GSE12945 28 34 62 Colorectal cancer
GSE14333 106 120 226 Colorectal cancer
GSE17536 81 96 177 Colorectal cancer
GSE17537 29 26 55 Colorectal cancer
GSE4271 32 68 100 Other cancer: glioma
GSE31684 25 68 93 Other cancer: bladder
GSE34111 6 24 30 Other cancer: gastrointestinal
GSE5720 24 30 54 Other cancer: 9 different tissues
GSE42952 9 14 23 Other cancer: pancreatic
GSE19027 11 48 59 Bronchial epithelium of (non-) smokers with and without lung cancer
GSE17913 38 40 78 Smoking
GSE23343 7 10 17 Insulin resistance/type 2 diabetes
GSE25462 28 22 50 Insulin resistance/type 2 diabetes
GSE7821 28 12 40 Healthy twins
GSE20950 27 12 39 Insulin resistance/obesity
GSE24427 80 45 125 Multiple sclerosis
GSE11121 200 0 200 Breast cancer
GSE2034 286 0 286 Breast cancer
TRANSBIG (GSE7390/GSE6532) 280 0 280 Breast cancer
GSE16446 114 0 114 Breast cancer; chemo response
GSE20194 247 0 247 Breast cancer; chemo response
GSE20271 139 0 139 Breast cancer; chemo response
GSE22093 47 0 47 Breast cancer; chemo response
GSE23988 60 0 60 Breast cancer; chemo response
Bild 133 0 133 Ovarian cancer
GSE14764 80 0 80 Ovarian cancer
GSE19829 28 0 28 Ovarian cancer
GSE26712 185 0 185 Ovarian cancer
GSE17951 0 153 153 Prostate cancer
GSE25136 0 79 79 Prostate cancer
GSE3325 0 19 19 Prostate cancer
GSE8218 0 148 148 Prostate cancer
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was clearly located in the female XIST expression range. 
RPS4Y1 and DDX3Y showed the opposite behavior, with 
high expression values observed in male patients. RPS4Y1 
encodes a structurally conserved ribosomal protein with 
putative function during spermatogenesis (Lopes et al. 
2010), whereas DDX3Y is primarily expressed in testis and 
is involved in germ-line translation control (Rauschendorf 
et al. 2011). Probe sets with low discriminating power were 
not included in the classifier. 
The expression levels of the four selected probe sets 
were evaluated in 35 additional datasets, including seven 
colon cancer, five other cancer, and seven non-cancer data-
sets containing samples from both male and female sub-
jects, as well as eight breast cancer, four ovarian cancer, 
and four prostate cancer datasets. A plot of raw expression 
values for the probe set 201909_at (RPS4Y1) across all 
datasets showed high male–female classification accuracy 
per dataset, but large overall expression shifts between 
datasets (Fig. 2a). After normalizing expression values with 
a linear transformation to median values of 0 and 1 for the 
low and high expression groups, respectively (Suppl. mate-
rial: Algorithm 2), expression levels were reliably compara-
ble across cohorts (Fig. 2b).
In a final step, the four sex-specific probe sets were com-
bined to categorize each sample as “correctly classified,” 
“misclassified,” or “unconfident” (Suppl. material: Algo-
rithm 3). First, for each cohort and for each probe set, the 
expression values were clustered into two groups of low 
and high values and a normal distribution was fitted to the 
low expression group, estimating location and scale with 
robust measures (median and Rousseeuw–Croux estima-
tor Qn (Rousseeuw and Croux 1993)). Next, the expression 
value of the probe set for each sample was compared to the 
99.9 % quantile of the fitted normal distribution. A value 
above this cut point is inconsistent with the typical range 
for the low expression group and thus provides strong evi-
dence that the corresponding sample belongs to the high 
expression group. For each individual sample, a female-
evidence score was then defined for each of the two XIST 
probe sets. As high XIST expression is inconsistent with 
male sex, the female-evidence score was set to 1 if the cor-
responding XIST expression value was above the cut point. 
Analogously, for DDX3Y and RPS4Y1, respectively, a 
male-evidence score was set to 1 if the expression value of 
the probe set was above the corresponding cut point. Tak-
ing the evidence scores of all four probe sets into account, 
a sample was classified as male if at least one male-evi-
dence score was 1 and both female-evidence scores were 
0. Vice versa, a sample was classified as female if at least 
one female-evidence score was 1 and both male-evidence 
scores were 0. Finally, the new classifications were com-
pared to the original sex annotations, categorizing each 
sample as “correctly classified,” “misclassified,” or “uncon-
fident.” Samples with both at least one positive female-
evidence score and at least one positive male-evidence 
score, or with no positive evidence score, were classified as 
“unconfident.”
Table 3  Probe sets included in 
the male–female classifier
Probe sets included into the male–female classifier, with corresponding cut points for evidence whether a 
sample originates from a male or a female




221728_x_at XIST X >0.389 Female
214218_s_at XIST X >0.385 Female
201909_at RPS4Y1 Y >0.431 Male
205000_at DDX3Y Y >0.276 Male
Fig. 1  Differentiation between male and female samples by 
XIST expression. Bean plots of the expression values of probe set 
221728_x_at (XIST) in the NSCLC cohort GSE31210. A clear 
separation between low expression values in males (blue) and high 
expression values in females (red) can be observed. One sample is 
mislabelled
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Results and discussion
The male–female classifier was applied to all 45 cohorts, 
categorizing 4913 patients (3034 females, 1879 males) 
(Fig. 3). In total 54 patients (1.1 %) were categorized as 
“misclassified” and 149 (3.0 %) were labelled “unconfi-
dent.” The direction of sex mislabeling was nearly bal-
anced, with 29 female samples mislabeled as male and 25 
male samples mislabeled as female. Overall, in 18 of the 
45 cohorts (40 %) at least one “misclassified” sample was 
detected. The proportion of “correctly classified” sam-
ples was 100 % in 15 cohorts, below 90 % in five cohorts, 
and in between for the remaining 25 cohorts. Note that 
these numbers are probably overoptimistic, as 16 cohorts 
included in the study consisted of breast, ovarian, or pros-
tate cancer patients, with lower risk of sex mislabeling. 
Still, one breast cancer patient in the cohort TRANSBIG 
(comprising node-negative untreated patients of GSE7390 
and GSE6532) was classified as male (Fig. 3).
The prevalence of sample identity inconsistencies in 
public data repositories can be anticipated to be at least 
twice as high as indicated by the male–female classifier, 
as mix-up may occur also between samples from individu-
als of the same sex. To visualize the expression-based sex 
assignment per cohort, we plotted mean normalized expres-
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Fig. 2  Improvement in comparability of cohorts by normalization. a 
Raw expression values of female (red) and male (blue) labelled sam-
ples set 201909_at (RPS4Y1) across all datasets. b The same cohorts 
after normalization. Specifically, two outliers in datasets TRANSBIG 
and GSE22093 indicate two breast cancer patients with high RPS4Y1 
expression, feature clearly inconsistent with female sex

























































































































































































































































































































































































































lung cancer others − both sexes others − one sex
Fig. 3  Application of the male–female classifier. Application of the male–female classifier to all cohorts, cohorts grouped by caner type. Green 
“correctly classified,” red “misclassified,” and orange “unconfident” samples
Fig. 4  Visualization of the 
male–female classifier with 
mean expression values of the 
two prove sets for XIST on 
the x-axis and DDX3Y and 
RPS4Y1 on the y-axis. The 
points represent individual 
patients. The point clouds on 
the left and are characteristic for 
males and females, respectively. 
Colors indicate classification 
accuracy samples. Green “cor-
rectly classified,” red “misclas-
sified,” and orange “unconfi-
dent.” a Results for the Uppsala 
cohort (GSE37745): One female 
patients clearly mislabeled 
as male, and two samples are 
labeled “unconfident.” b Results 
for GSE33113 with clear dis-
crimination between males and 
females and no sex misannota-
tions. c Results for GSE5720 
with two misclassified samples 
and large number of samples 
classified as “unconfident.”  
d Results for a breast cancer 
dataset (TRANSBIG) with one 
male patient assigned to the 
category “misclassified”
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two Y-chromosomal probe sets against each other (Fig. 4). 
For most cohorts, two clearly distinguishable groups repre-
senting males and females can be recognized, and category 
assignment by visual inspection is well in agreement with 
our likelihood-based classifier.
A further error that may occur during tissue process-
ing is sample duplication. The same sample may be ana-
lyzed twice and the duplicate is erroneously labelled with 
the identification number of another patient. To identify 
such duplications, a correlation-based analysis strategy was 
applied. For each cohort, the 1000 probe sets with highest 
variance across all samples were selected and Pearson corre-
lation coefficients between all pairs of samples in the cohort 
were calculated. The largest distance between all ordered 
values of correlations was identified to distinguish between 
duplicated measurements and pairs of measurements from 
different samples. In 15 of the 45 cohorts at least one dupli-
cate was identified. In total 32 duplicates were detected. 
Comparing these duplicates with the results from the male–
female classifier, nine of the 54 “misclassified” assignments 
(16.7 %) could be explained by duplicated measurements.
The general impact of misannotated samples on gene 
expression is difficult to assess. To illustrate the relevance 
of misannotations in gene expression studies, we re-ana-
lyzed six lung cancer cohorts with available survival times. 
Prognostic relevance of a gene was determined by fitting 
a univariate Cox model (Cox 1972) to its expression val-
ues. The number of significant genes (p value <0.01; not 
FDR-adjusted) was first calculated for the original datasets. 
Removing all unambiguously misannotated samples from 
the six datasets with misannotations, 12–53 % of the pre-
viously significant genes were not significant any more. 
In contrast, using only the reduced number of samples, 
the number of newly discovered genes was in the range 
of 9–39 % of the original number of significant genes 
(Table 4).
To elucidate the reason behind the sample mislabeling 
observed in our own non-small cell lung cancer cohort 
(GSE37745), one patient annotated as male in the origi-
nal records and assigned as female by our classifier was 
re-analyzed. First, new DNA and RNA samples were pre-
pared from the original biobanked tissue specimen. Male 
sex was then confirmed based on the analysis of STR 
marker distribution using the AmpFLSTR® Identifiler® 
PCR Amplification Kit according to the manufacturer’s 
instructions (Applied Biosystems, Foster City, USA), sug-
gesting that sample mix-up in this case did not occur dur-
ing sample collection and biobanking procedures. Subse-
quently, the gene expression array analysis was repeated 
for the misclassified sample and for five additional control 
samples from the previously analyzed cohort. The pairwise 
correlation between the new and old misclassified sample 
was only 0.464, strongly indicating that these two sam-
ples were derived from different individuals. In contrast, 
a striking correlation of 0.993 was detected between the 
misclassified sample and a sample from one other female 
patient in the previously analyzed cohort. The high cor-
relation suggests that the mRNA sample from one female 
patient erroneously had been measured twice in the pre-
vious analysis. A second duplicated measurement was 
detected, with correlation 0.990 between the expression 
values of two patients with sex label male. In contrast, all 
correlations of the repeated control samples with the cor-
responding original measurements were high (correlation 
coefficients: 0.910–0.987).
The rapidly increasing number of newly published 
results of microarray and RNA-seq experiments reveals 
that genome-wide expression data play an important role 
in translational research (Petermann et al. 2007; Verhaak 
et al. 2013). Therefore, quality control for gene expres-
sion measurements and clinical information on sam-
ples should be performed routinely before analyzing 
the data. Retrospective identification of misannotated 
samples is possible by a classifier-based computational 
strategy together with correlation analysis. In 18 of 45 
cohorts analyzed at least one “misclassified” sample 
Table 4  Results of univariate Cox models
Results of univariate Cox models for six NSCLC datasets. Comparison between significance genes (p < 0.01) identified in the original cohort 
and significance genes identified in the reduced cohort after removal of misannotated and duplicated samples
Dataset No. of 
patients
No. of misannotations and 
duplications
No. of significant genes 
(original scenario)
Percentage of genes no longer 
significant after removal of the 
misannotated samples
Percentage of genes newly 
significant after removal of 
the misannotated samples
GSE37745 196 3 450 12.22 14.00
Shedden 443 14 1354 15.66 8.79
GSE29013 55 1 419 15.51 14.32
GSE4573 129 5 189 26.63 38.62
GSE31547 50 1 318 50.51 23.27
GSE19188 82 8 190 53.16 34,374
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was detected. The easy-to-use classifier presented here, 
combined with correlation analysis to detect samples 
erroneously measured multiple times, helps to identify 
individual datasets that contain numerous discrepan-
cies. Re-evaluation of gene expression array data dem-
onstrated that sample mislabeling may have a consider-
able impact on the output of the statistical evaluation and 
allows inferences on the accuracy of biobanking. In con-
clusion, methods for identifying sample misannotations 
should be routinely included into the statistical analysis 
of clinical gene expression data.
Acknowledgments This work was supported by the German 
Research Foundation (DFG, contract numbers RA 870/4-1 and RA 
870/5-1), and the Swedish Cancer Society.
Compliance with ethical standards 
Conflict of interest The authors declare no conflict of interest.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole 
D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, Dressman HK, 
West M, Nevins JR (2006) Oncogenic pathway signatures in human 
cancers as a guide to targeted therapies. Nature 439:353–357
Broman KW, Keller MP, Broman AT, Kendziorski C, Yandell BS, 
Sen S, Attie AD (2015) Identification and correction of sample 
mix-ups in expression genetic data: a case study. G3. Bethesda 
5(10):2177–2186. doi:10.1534/g3.115.019778
Cox DR (1972) Regression models and life tables: a case study. 
J R Stat Soc Series B Stat Methodol 34(2): 187–220a. 
arXiv:1402.2633 [stat.AP]
Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: 
NCBI gene expression and hybridization array data repository. 
Nucleic Acids Res 30:207–210
Lopes AM, Miguel RN, Sargent CA, Ellis PJ, Amorim A, Affara 
NA (2010) The human RPS4 paralogue on Yq11.223 encodes 
a structurally conserved ribosomal protein and is preferentially 
expressed during spermatogenesis. BMC Mol Biol 11:33
Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, 
Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas 
NE, Serody JS, Sharpless NE (2007) CD200 is induced by ERK 
and is a potential therapeutic target in melanoma. J Clin Invest 
117(12):3922–3929
Rauschendorf MA, Zimmer J, Hanstein R, Dickemann C, Vogt 
PH (2011) Complex transcriptional control of the AZFa gene 
DDX3Y in human testis. Int J Androl 34(1):84–96
Rousseeuw PJ, Croux C (1993) Alternatives to the median absolute 
deviation. J Am Stat Assoc 88(424):1273–1283
Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald 
WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, 
Zhu CQ, Strumpf D et al (2008) Gene expression-based survival 
prediction in lung adenocarcinoma: a multi-site, blinded valida-
tion study. Nat Med 14(8):822–827
‘t Hoen PA, Friedländer MR, Almlöf J, Sammeth M, Pulyakhina I, 
Anvar SY, Laros JF, Buermans HP, Karlberg O, Brännvall M, 
GEUVADIS Consortium, den Dunnen JT, van Ommen GJ et al 
(2013) Reproducibility of high-throughput mRNA and small RNA 
sequencing across laboratories. Nat Biotechnol 31(11):1015–1022
Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton 
CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, 
Etemadmoghadam D, Saksena G (2013) Prognostically relevant 
gene signatures of high-grade serous ovarian carcinoma. J Clin 
Invest 123(1):517–525
Westra HJ, Jansen RC, Fehrmann RS, te Meerman GJ, van Heel D, 
Wijmenga C, Franke L (2011) MixupMapper: correcting sam-
ple mix-ups in genome-wide datasets increases power to detect 
small genetic effects. Bioinformatics 27(15):2104–2111
